Last Friday, exactly one year after previously receiving a CRL from the FDA, AcelRx Pharmaceuticals' (ACRX) lead drug candidate Dsuvia received a 10-3 vote from an FDA Advisory Committee - according to the Advisory Committee, the benefits of approving Dsuvia for use in a medically supervised setting outweigh the risks. As a result, it seems likely that the FDA will issue an official approval for Dsuvia sometime in the weeks leading up to the drug's November 3 PDUFA date. However, ACRX's stock has been performing poorly, contrary to general expectations. On Tuesday, ACRX